¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ±è¼öÁöÀÔ´Ï´Ù.
Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2021³â Cell reports ¿¡ ÃâÆǵÈ
"A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge
" ÀÔ´Ï´Ù.
º» ³í¹®¿¡¼´Â SARS-CoV-2 ÀÇ N protein °ú full S protein ¿¡ flagellin, cyclic GMP-AMP ¸¦ ÇÕÃÄ Èĺ¸ ¹é½ÅÀ» ¸¸µé¾ú°í ÀÌ Èĺ¸ ¹é½ÅÀÌ systemic, mucosal humoral immunity ¸¦ °ÇÏ°Ô ÀÏÀ¸Å°´Â °ÍÀ» È®ÀÎÇß½À´Ï´Ù. ¶ÇÇÑ ÀÌ ¹°ÁúÀº intranasal route ¸¦ ÀÌ¿ëÇÏ¿© È£Èí±â°ü¿¡ ¸é¿ª¹ÝÀÀÀ» Çâ»ó½ÃÄ×À¸¸ç human ACE2 transgenic mice ¿¡¼µµ º¸È£È¿°ú¸¦ ³ªÅ¸³»´Â °ÍÀ» È®ÀÎÇÏ¿´½À´Ï´Ù.
SARS-CoV-2 ¹é½Å, adjuvant °ü·Ã Èĺ¸¹°Áú¿¡ ´ëÇÑ ½ÇÇèµðÀÚÀÎÀ» °øºÎÇغ¸°íÀÚ ¼±Á¤Çß½À´Ï´Ù.
Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
³í¹®»çÀÌÆ®: A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge - ScienceDirect